Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099944 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 515
- Enrollment target
NCT00099944: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00099944 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 515 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099944, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 515 participants
- Enrollment target
Study Summary
Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to glimepiride in people with type 2 diabetes not at target blood glucose levels on a sulfonylurea alone.
Interventions
- DRUG Glimepiride
- DRUG vildagliptin
- DRUG LAF237 placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 515 participants |
| Start Date | 2004-05 |
| Est. Completion | 2005-10 |
| Phase | Phase 3 |
What the finished NCT00099944 record still lists
NCT00099944 is an interventional study that assigns participants to a tested intervention. The registered 515 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (33% lower).
The record links to 0 conditions, and to 3 interventions - of which Glimepiride is the first listed.
NCT00099944 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00099944 about?
NCT00099944 is a clinical study titled "Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes". Many people with type 2 diabetes cannot maintain target blood glucose levels when taking a single oral drug. The purpose of this study is to assess the safety and effectiveness of two doses of vildagliptin, an unapproved drug, in lowering overall blood glucose levels when added to glimepiride in peo...
What is the current status of trial NCT00099944?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 515 participants. The study started on 2004-05. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00099944?
The interventions under investigation include: Glimepiride (DRUG), vildagliptin (DRUG), LAF237 placebo (DRUG).
Who is sponsoring clinical trial NCT00099944?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00099944's enrollment target sits among peer trials
515 724th of 2000 higher than 1,277 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05577819 · 515 participants · NA
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
- NCT06804837 · 515 participants · NA
Implement and Test Visual Consent Template and Process
- NCT05933083 · 516 participants · NA
MCNAIR Study: coMparative effeCtiveness of iN-person and teleheAlth cardIac Rehabilitation
- NCT05691244 · 514 participants · Phase 3
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia